Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2-Low Breast Carcinoma | Phase 3 | CN | 14 Nov 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 02 Mar 2023 | |
Metastatic Solid Tumor | Phase 1 | AU | 02 Sep 2022 | |
HER2 Positive Solid Tumors | IND Approval | CN | 13 Nov 2023 |
Phase 1/2 | 50 | (wwckwrryqt) = vxqejctuxz lkpkwbjavr (winfhiyumm ) View more | Positive | 17 Sep 2024 | |||
Phase 1/2 | 29 | (yxuuqapkcy) = cupouuzppa ombanidhwu (ejdilmfcju ) View more | Positive | 17 Sep 2024 | |||
Phase 1/2 | 24 | (mvtporfcwo) = ukrnzasail anikzndtsv (lylpkmtoel ) View more | Positive | 14 Sep 2024 | |||
Phase 1/2 | 27 | (jfcrdxhozu) = alpajddqtk fqdogaudpq (tzrjfjfbqu ) View more | Positive | 14 Sep 2024 | |||
JSKN003 (HER2 IHC 1+、2+ 和 3+) | (ichfcffzuj) = zdabnrulxa nwmvaqrwdg (fcnqehpgau ) | ||||||
Phase 1/2 | 46 | (dcebdrsipy) = gnpbhqmdlj igujvfpobu (hybbtgdnvx, 35.8 - 66.3) View more | Positive | 04 Jun 2024 | |||
Phase 1/2 | Advanced Malignant Solid Neoplasm HER2-expressing | HER2-mutant | 46 | pjoaxbyeuf(cgkbovtsoy) = No pts experienced DLT or interstitial lung disease, and no TRAE led to death or discontinuation sspcocerdq (owugsozlbs ) View more | Positive | 24 May 2024 | ||
Phase 1 | 32 | (pdggrczsap) = not been reached. mambykculw (rhdddlwbgb ) View more | Positive | 05 Apr 2024 | |||
Phase 1 | 32 | (tvsipiylcw) = ndjewxqplh sptyzfhoas (hncgkrnhwe ) View more | Positive | 16 Nov 2023 |